Human Growth Hormone A Case Study in Treatment Priorities
Bibliographic Data
| ID | 20333310 |
|---|---|
| Authors | Carol A Tauer (St. Catherine University, corresponding author) |
| Year | 1995 |
| Volume | 25 |
| Issue | 3 |
| Pages | S18 |
| Publication date | 1995-05-01 |
| Open Access | No |
| Type | ARTICLE |
| Venue | The Hastings Center Report (JOURNAL) |
| Journal identifiers | ISSN: 0093-0334 • E-ISSN: 1552-146X |
| Publisher | JSTOR (PUBLISHER) |
| DOI | 10.2307/3562126 |
| PMID | 11654186 |
| OpenAlex | W2086962617 |
| Language | EN |
| Citations received | 2 |
| References cited | 3 |
One of the most commonly cited examples of enhancement genetic engineering is insertion of the growth hormone (GH) gene into a medically normal child. At this time, insertion of the gene itself is not planned. However, the modification of height, which is possible through administration of biochemical GH, raises the same questions about therapeutic versus enhancement uses of genetics. While insertion of the gene is a more drastic measure and probably carries more risks, the question of appropriate limits on use of the GH drug raises similar ethical and policy questions
Bioinformatics · Biology · Food and drug administration · Gene · Growth hormone · Hormone · Human growth hormone · Diet and metabolism studies · Genetics · Growth Hormone and Insulin-like Growth Factors · Internal Medicine · Medicine · Pharmacology
| Citations per year | 0.18 |
|---|---|
| Citation span | 2015 - 2015 (1) |
| Highly cited | No |